Non-Hodgkin's Lymphoma News

CancerConnect non-Hodgkin’s lymphoma news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to ovarian cancer. The unique daily cancer news service evaluates all aspects of non-Hodgkin’s lymphoma research and reports on the developments that are most important to cancer patients and healthcare providers, while the tips and features offer insight into all aspects of non-Hodgkin’s lymphoma treatment and survivorship.

Share

Non-Hodgkin's Lymphoma News


Upcoming Educational Forum for Waldenstrom’s Macroglobulinemia Patients and Caregivers (March 9, 2017)

The 22nd Annual IWMF Educational Forum May 19-21, 2017, in Phoenix, Arizona The International Waldenstrom’s Macroglobulinemia Foundation (IWMF) is a patient-founded and patient-led, nonprofit organization... Continue Reading

2016-Year in Review: Advances in Management of Lymphomas (February 16, 2017)

Our understanding of lymphomas has allowed scientists to find new and unique ways of treating this blood cancer. Lymphoma treatments have expanded far beyond chemotherapy, though that type of treatment... Continue Reading

Imbruvica® is approved by FDA for Marginal Zone Lymphoma (February 7, 2017)

The U.S. Food and Drug Administration (FDA) has approved Imbruvica® (ibrutinib) for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least... Continue Reading

Gazyva® Delays Cancer Progression as Initial Therapy in Advanced Follicular Lymphoma (January 5, 2017)

Among patients with advanced follicular lymphoma who have not received prior therapy, treatment with Gazyva® (obinutuzumab) plus chemotherapy delays cancer progression compared to the standard Rituxan®... Continue Reading

Progress Reported in New Treatments for People with Lymphoma (December 29, 2016)

Research and pharmaceutical executives unveil encouraging clinical trial data at the annual meeting of the American Society of Hematology. Twenty-two years ago, Dr. Gary Gordon, Ph.D., vice president of... Continue Reading

Gazyva® Improves Outcomes Compared to Rituxan® in Untreated Follicular Lymphoma (December 15, 2016)

Treatment including the targeted agent Gazyva (obinutuzumab) delays cancer progression for a longer period of time than treatment with Rituxan (rituximab) among patients with follicular lymphoma who have... Continue Reading

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions (December 1, 2016)

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring transfusions. These results were recently published... Continue Reading

The First CAR-T Therapy Heading to the FDA (September 29, 2016)

Kite Pharma reported that its CAR-T therapy demonstrated a 39% response rate, including a 33% complete response rate, in patients with aggressive non Hodgkin lymphoma. The interim results from the phase... Continue Reading

Opdivo® Highly Effective for Some Patients with Lymphomas (August 16, 2016)

The immunotherapeutic agent, Opdivo® (nivolumab), appears to provide long-lasting anti-cancer activity among some patients who have received extensive prior therapy for both B- and T-cell lymphomas. These... Continue Reading

CancerConnect Launches Online Community for Patients Diagnosed with Histiocytosis (June 24, 2016)

Sun Valley ID & Austin TX– OMNI Health Media (OMNI) announces the launch of a new online community on CancerConnect for adults affected by histiocytosis. This community will provide patients and... Continue Reading

More Non-Hodgkin's Lymphoma News

Latest Non-Hodgkin's Lymphoma News By Stage


Screening and Prevention

What’s New in the Management of Lymphoma? (March 2, 2015)

What’s New in the Management of Lymphoma? Cancers that begin in cells of the lymph system are referred to as malignant lymphomas. Lymphomas range from aggressive to slow growing or indolent and can be effectively treated. The lymph system includes the... Continue Reading

September Is National Blood Cancer Awareness Month (September 5, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of blood cancer educational programs for national blood cancer awareness month. As the month of September brings blood cancers into focus, it’s time to increase public... Continue Reading

Link Between Allergies and Blood Cancers in Women (January 1, 2014)

Researchers have found a link between airborne allergies and the risk of blood cancers in women, according to the results of a study published in the American Journal of Hematology. Cancer research has increasingly become focused on the immune system... Continue Reading

Celiac Disease Associated with Higher Risk of Lymphoma (September 4, 2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

More Screening and Prevention

Indolent/Low Grade

Upcoming Educational Forum for Waldenstrom’s Macroglobulinemia Patients and Caregivers (March 9, 2017)

The 22nd Annual IWMF Educational Forum May 19-21, 2017, in Phoenix, Arizona The International Waldenstrom’s Macroglobulinemia Foundation (IWMF) is a patient-founded and patient-led, nonprofit organization that is dedicated to a simple but compelling... Continue Reading

Gazyva® Delays Cancer Progression as Initial Therapy in Advanced Follicular Lymphoma (January 5, 2017)

Among patients with advanced follicular lymphoma who have not received prior therapy, treatment with Gazyva® (obinutuzumab) plus chemotherapy delays cancer progression compared to the standard Rituxan® (rituximab) plus chemotherapy, and should now be... Continue Reading

The First CAR-T Therapy Heading to the FDA (September 29, 2016)

Kite Pharma reported that its CAR-T therapy demonstrated a 39% response rate, including a 33% complete response rate, in patients with aggressive non Hodgkin lymphoma. The interim results from the phase II clinical trial are promising enough for Kite... Continue Reading

Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in Follicular Lymphoma (June 8, 2016)

A study in people with previously untreated follicular lymphoma, the most common type of indolent (slow-growing) non-Hodgkin’s lymphoma (iNHL) suggests that  Gazyva® (obinutuzumab) plus chemotherapy (CHOP, CVP or bendamustine) followed by Gazyva alone... Continue Reading

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood cancer treatments, the role of clinical trials... Continue Reading

More Indolent/Low Grade

Highly Aggressive/High Grade

The First CAR-T Therapy Heading to the FDA (September 29, 2016)

Kite Pharma reported that its CAR-T therapy demonstrated a 39% response rate, including a 33% complete response rate, in patients with aggressive non Hodgkin lymphoma. The interim results from the phase II clinical trial are promising enough for Kite... Continue Reading

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading

Novel Immunotherapy Trial for Lymphoma Offers Hope to Patients at Sylvester (May 27, 2016)

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine are testing a novel cellular immunotherapy approach to treating patients with diffuse large B-cell lymphoma who have failed standard therapy. This... Continue Reading

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood cancer treatments, the role of clinical trials... Continue Reading

What’s New in the Management of Lymphoma? (March 2, 2015)

What’s New in the Management of Lymphoma? Cancers that begin in cells of the lymph system are referred to as malignant lymphomas. Lymphomas range from aggressive to slow growing or indolent and can be effectively treated. The lymph system includes the... Continue Reading

More Highly Aggressive/High Grade

Mantle Cell

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading

Revlimid®/Rituxin® Highly Active as Initial Therapy for Mantle Cell Lymphoma (December 10, 2015)

The treatment combination consisting of Revlimid® (lenalidomide) plus Rituxan® (rituximab) provides high rates of long-lasting anti-cancer responses when used as initial therapy for mantle cell lymphoma. These results were recently published in the... Continue Reading

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood cancer treatments, the role of clinical trials... Continue Reading

What’s New in the Management of Lymphoma? (March 2, 2015)

What’s New in the Management of Lymphoma? Cancers that begin in cells of the lymph system are referred to as malignant lymphomas. Lymphomas range from aggressive to slow growing or indolent and can be effectively treated. The lymph system includes the... Continue Reading

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment (December 17, 2014)

CancerConnect News: HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection... Continue Reading

More Mantle Cell

T-Cell

The First CAR-T Therapy Heading to the FDA (September 29, 2016)

Kite Pharma reported that its CAR-T therapy demonstrated a 39% response rate, including a 33% complete response rate, in patients with aggressive non Hodgkin lymphoma. The interim results from the phase II clinical trial are promising enough for Kite... Continue Reading

Opdivo® Highly Effective for Some Patients with Lymphomas (August 16, 2016)

The immunotherapeutic agent, Opdivo® (nivolumab), appears to provide long-lasting anti-cancer activity among some patients who have received extensive prior therapy for both B- and T-cell lymphomas. These results were recently published in the Journal... Continue Reading

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading

CART Therapy Promising in Lymphomas (February 9, 2016)

The use of a patient’s own immune cells to fight cancer through a technique called CART therapy, is proving to be a promising therapeutic approach in the treatment of some lymphomas. These results were presented at the 2015 annual meeting of the American... Continue Reading

Deadly and distinctive: Cancer caused by gene deletions (July 28, 2015)

By Bill Hathaway A deadly form of T cell lymphoma is caused by an unusually large number gene deletions, making it distinct among cancers, a new Yale School of Medicine study shows. Researchers conducted a genomic analysis of normal and cancer cells from... Continue Reading

More T-Cell

Recurrent

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood cancer treatments, the role of clinical trials... Continue Reading

What’s New in the Management of Lymphoma? (March 2, 2015)

What’s New in the Management of Lymphoma? Cancers that begin in cells of the lymph system are referred to as malignant lymphomas. Lymphomas range from aggressive to slow growing or indolent and can be effectively treated. The lymph system includes the... Continue Reading

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment (December 17, 2014)

CancerConnect News: HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection... Continue Reading

Adding Revlimid to R-CHOP May Improve Outomes of Selected Patients with NHL (September 4, 2014)

The results of a recently completed study reported in the Journal of Clinical Oncology indicate that the addition of Revlimid® (lenalidomide) to R-CHOP the standard treatment for non hodgkin lymphoma (NHL) can overcome the negative prognostic effect... Continue Reading

More Recurrent

Aggressive/Intermediate Grade

The First CAR-T Therapy Heading to the FDA (September 29, 2016)

Kite Pharma reported that its CAR-T therapy demonstrated a 39% response rate, including a 33% complete response rate, in patients with aggressive non Hodgkin lymphoma. The interim results from the phase II clinical trial are promising enough for Kite... Continue Reading

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading

Novel Immunotherapy Trial for Lymphoma Offers Hope to Patients at Sylvester (May 27, 2016)

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine are testing a novel cellular immunotherapy approach to treating patients with diffuse large B-cell lymphoma who have failed standard therapy. This... Continue Reading

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood cancer treatments, the role of clinical trials... Continue Reading

What’s New in the Management of Lymphoma? (March 2, 2015)

What’s New in the Management of Lymphoma? Cancers that begin in cells of the lymph system are referred to as malignant lymphomas. Lymphomas range from aggressive to slow growing or indolent and can be effectively treated. The lymph system includes the... Continue Reading

More Aggressive/Intermediate Grade

CancerConnect Cancer Commuity & Discussions


Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS